Background and Purpose: Polatuzumab vedotin is an antibody-drug conjugate (ADC) being developed for non-Hodgkin's lymphoma. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), an anti-mitotic agent. Polatuzumab vedotin binds to human CD79b only. Therefore, a surrogate ADC that binds to cynomolgus monkey CD79b was used to determine CD79b-mediated pharmacological effects in the monkey and to enable first-inhuman clinical trials.
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Conclusions and Implications: The suitability of the surrogate ADC for evaluation of CD79b-dependent pharmacology was demonstrated, and anti-tumour activity, pharmacokinetics/pharmacodynamics, and toxicity data with both ADCs supported the entry of polatuzumab vedotin into clinical trials.
| INTRODUCTION
Non-Hodgkin's lymphoma (NHL) is the most common haematological malignancy in adults. Despite improvements in clinical outcomes of patients, approximately half of patients with aggressive NHLs are refractory to or relapse following available standard of care therapies (Campo et al., 2011; Fisher, Miller, & O'Connor, 2004; Hennessy, Hanrahan, & Daly, 2004) . Thus, there is a large unmet need for new treatments. Antibody-drug conjugates (ADCs) represent a class of therapeutics (Beck, Goetsch, Dumontet, & Corvalia, 2017 ) that aim to deliver chemotherapy selectively to cancer cells using tumourtargeting monoclonal antibodies (mAbs). Gemtuzumab ozogamicin, ado-trastuzumab emtansine, brentuximab vedotin, and inotuzumab ozogamicin are ADCs that have been approved for cancer therapy (Damle & Frost, 2003; Diamantis & Banerji, 2016; Piccaluga et al., 2011) . Polatuzumab vedotin is an anti-CD79b ADC being developed for the treatment of NHL (NCT01290549, 2017; Palanca-Wessels et al., 2015) . The structure and mechanism of action of polatuzumab vedotin are described in Figure 1 (Caculitan et al., 2017; Doronina et al., 2003; Sutherland et al., 2006) . CD79b is a surface antigen whose expression is restricted to pre-B and mature B cells. CD79b is expressed on nearly all major subtypes of B-cell-derived NHL (Dornan et al., 2009; Polson et al., 2009) . Antibodies that bind to CD79b rapidly internalize and traffic to the lysosomal compartment, making CD79b a suitable tumour antigen for targeted delivery of cytotoxic agents (Polson et al., 2007; Zheng et al., 2009) .
A challenge for the non-clinical development of polatuzumab vedotin was that this ADC only binds to CD79b on B cells of humans but not on those of mouse, rat, or cynomolgus monkey, resulting in the lack of a pharmacologically relevant non-clinical species to evaluate antigen-dependent pharmacokinetics (PK), pharmacology, and safety prior to first-in-human trials (ICH S6, 2011 and ICH S9, 2009 ).
In such cases, alternative approaches to the non-clinical assessment of antibody-based therapeutics can include the use of surrogate molecules, surrogate animal models, or in vitro pharmacological systems (ICH S6, 2011 and ICH S6 addendum, 2012) .
Non-human primates are considered an appropriate species for non-clinical development of most antibody-based therapeutics because of their biological similarity to humans as shown by target expression, distribution, and pharmacological activity (Deng et al., 2011) . Anti-murine surrogate antibodies are often used in the development of antibody-based therapeutics (Bussiere et al., 2009 ). However, the mouse is not considered an appropriate species for toxicological assessments of auristatin/dolastatin-containing ADCs because mice are not sensitive to the effects of these cytotoxic agents (Mirsalis et al., 1999) . In order to assess the pharmacology and toxicity of polatuzumab vedotin, we developed a surrogate ADC that binds to cynomolgus monkey CD79b at an epitope similar to where polatuzumab vedotin binds to human CD79b (Zheng et al., 2009) . A comprehensive evaluation of the surrogate ADC was performed to demonstrate its suitability. Studies with both ADCs provided relevant antigen-dependent and -independent pharmacology, PK, and safety information to support entry of polatuzumab vedotin into clinical trials. • There were no relevant non-clinical species to evaluate the pharmacological effects of polatuzumab vedotin.
What this study adds
• Non-clinical studies with a surrogate ADC provided relevant safety information to enable first-in-human trials.
• The principles for alternative testing approaches could potentially be applied to other biopharmaceuticals.
What is the clinical significance
• The use of the surrogate ADC provided an understanding of CD79b-dependent pharmacological activity in patients.
• Clinical adverse effects were predicted from the nonclinical pharmacology and toxicity assessments.
prior to dose administration. Studies were conducted following the SOP applicable to the Contract Research Organization (Covance, Inc.
[RRID:SCR_001224], for the rat study, or Charles River Laboratories International, Inc. [RRID:SCR_00379], for the cynomolgus monkey study). Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, Emerson, & Altman, 2010) and with the recommendations made by the British Journal of Pharmacology. All animals were purpose bred and experimentally naïve at the outset of the studies. Prior to study assignment, animals were quarantined, maintained, and monitored for good health in accordance to testing facility SOP and/or as mandated by the Centers for Disease Control and Prevention, Atlanta, Georgia. Environmental control in the animal rooms were set to maintain a temperature of 18-29°C (64-84°F), a relative humidity of 30-70%, minimum fresh air changes of 10 per hour, and a light/dark cycle of 12:12 hr. All animals were housed individually in stainless-steel cages but were allowed to comingle to provide psychological enrichment, with the exception of telemetry animals. Prior to dosing, animals were allowed to acclimate in their housing for a minimum of 2 weeks. Certified primate diet was provided daily and supplemented with fruits or vegetables 2-3 times a week as part of the Testing Facility's environmental enrichment programme. Water was provided ad libitum to each animal via automatic watering devices.
Cynomolgus monkeys were killed under deep, unrecoverable anaesthesia induced by ketamine and nembutal, or equivalent, followed by exsanguination. Rats were anaesthetized with sodium pentobarbital, and samples were collected for toxicokinetics (TK) and anti-drug antibody analysis, exsanguinated, and necropsied.
| Generation of antibodies and ADCs
The antibody for polatuzumab vedotin was generated and then humanized, and the antibody for surrogate ADC was generated as a mouse/human chimeric antibody (Diamantis & Banerji, 2016; Gorovits et al., 2013; Polson et al., 2009 ). ADCs were made as described previously (Gorovits et al., 2013) . Briefly, ADCs were prepared by incubating the maleimide drug derivative with the partially reduced antibodies for 1 hr at 4°C. After quenching the reaction with excess N-acetylcysteine to react with any free linker-drug, the conjugated antibody was purified. Conjugation conditions were chosen to achieve an average drug-to-antibody ratio (DAR) of approximately 3.5. ADC protein concentrations were calculated using absorbance at 280 nm (320-nm FIGURE 1 Chemical structure of polatuzumab vedotin and the surrogate antibody-drug conjugate (ADC). Polatuzumab vedotin consists of a humanized IgG1 antibody specific for human CD79b and is chemically conjugated to monomethyl auristatin E (MMAE) with a highly stable peptide linker (maleimidocaproyl [mc]valine-citrulline [vc]-paminobenzoyloxycarbonyl [PAB] ) that is selectively cleaved by lysosomal enzymes after internalization of the ADC. MMAE is a synthetic analogue of the natural product dolastatin. The intrachain cysteine disulfide bonds of the antibody are reduced, and the linker-MMAE is conjugated to the cysteines. With this method of conjugation, MMAE is coupled to an even number of cysteines (2, 4, 6, or 8) . The surrogate ADC has a similar structure to polatuzumab vedotin except it contains a chimeric IgG1 antibody specific for monkey CD79b. Polatuzumab vedotin and the surrogate ADC are a mixture of the mAb linked with 0, 2, 4, 6, or 8 vc-MMAE molecules with an average of 3.7 vc-MMAE molecules per antibody for polatuzumab vedotin and an average of 3.5 vc-MMAE molecules per antibody for the surrogate ADC. The mechanism of action involves ADC binding to CD79b, followed by its internalization, cleavage of the linker by lysosomal enzymes, and release of MMAE, a cytotoxin. MMAE binds to tubulin and disrupts the microtubule network, resulting in inhibition of cell division and cell death reference) and the molar extinction coefficient of the antibody. The average DARs were calculated from the integrated areas of the DAR species resolved by hydrophobic interaction chromatography on an analytical column (TSK butyl-NPR 4.6 mm, 10 cm, and 2.5 mm, Tosoh Bioscience).
| Cell lines
The NHL cell lines WSU-DLCL2 (DSMZ Cat# ACC-575, RRID: 
| Flow cytometry of peripheral blood
Human, cynomolgus monkey, and rat peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using a BD Vacutainer ® CPT™ according to the manufacture's protocol. Mouse PBMCs were isolated from whole blood by ACK lysis buffer treatment to lyse red blood cells followed by centrifugation to recover PBMCs. Human, cynomolgus monkey, rat, and mouse PBMCs were incubated with 10 μg·ml −1 of polatuzumab vedotin, surrogate ADC, or a human IgG isotype control labelled with Zenon Alexa Fluor 647 (Thermo Fisher Scientific). Samples were acquired on FACSCalibur flow cytometer (BD Biosciences [BD FACSCalibur Flow Cytometry System, RRID: SCR_000401]). Data were analysed using FlowJo (RRID: SCR_008520), and the geometric mean fluorescent intensity was calculated. A murine anti-human CD20 antibody (clone 2H7, BD Biosciences Cat# 555623, RRID:AB_395989) was used as a B-cell marker for both human and cynomolgus monkey PBMCs. A murine anti-rat CD45RA (clone OX33, BD Biosciences Cat# 551402, RRID: AB_394186) and a rat anti-mouse CD45R (clone RA3-6B2, BD Biosciences Cat# 553090, RRID:AB_394620) were used as B-cell markers for rat and mouse PBMCs, respectively.
| Binding affinity with human and cynomolgus monkey CD79b-expressing BJAB cell lines by equilibrium binding analysis
The binding affinity of polatuzumab vedotin, the surrogate ADC, and their corresponding unconjugated antibodies to human and cynomolgus monkey CD79b was determined by equilibrium binding analysis using transfected BJAB cells, a human Burkitt's lymphoma-derived B-cell line that expresses both human and cynomolgus monkey CD79b (Zheng et al., 2009) , in a radio-ligand competition cell-binding assay. The transfected BJAB cells were incubated for 2 hr at room temperature with a constant concentration of 125 I-labelled antibody and a dilution series of the non-labelled antibody. After incubation, the competition reactions were transferred to a filter bottom plate and washed. Filters containing 125 I-labelled antibody bound to cells were counted using a gamma counter. Data were analysed using the non-linear regression method of Munson and Rodbard (1980) to determine the binding affinity of the antibody.
| Binding activity to human Fcγ receptors
The Fcγ receptor-binding activities of polatuzumab vedotin, the unconjugated clinical antibody (the anti-human CD79b mAb used for polatuzumab vedotin conjugation), the surrogate ADC, and the unconjugated surrogate antibody (the anti-cynomolgus monkey CD79b mAb used for surrogate ADC conjugation) were measured by ELISA using a panel of recombinant human Fcγ receptors (IA, IIA-H131, IIA-R131, IIB, IIIA-F158, and IIIA-V158) as previously described (Chung et al., 2012) . For measuring binding to human FcγRII and FcγRIII, test antibodies were preincubated with anti-human κ light chain F(ab′) 2 to form a complex to increase binding avidity. Briefly, test antibodies were serially diluted and then added to plates coated with recombinant human FcγRs. Bound antibodies were detected using goat F(ab′) 2 -anti-human, F(ab′) 2 -HRP, and tetramethylbenzidine (TMB). Dose-response binding curves were generated by plotting the mean absorbance values from duplicates of sample dilutions against the sample concentrations and fitted with a four-parameter model using SoftMax Pro (Molecular Devices [SoftMax Pro Data Acquisition and Analysis Software, RRID:SCR_014240]). For comparison, the EC 50 value of the reference molecule was set at 1, and the relative activity of each sample was calculated as follows:
Relative Activity ¼ Reference EC 50 Sample EC 50 :
| In vitro plasma stability studies
Freshly frozen human, cynomolgus monkey, rat, and mouse plasma (lithium-heparin; Bioreclamation, Inc. [RRID:SCR_004728]) were thawed, centrifuged at 228× g (Beckman CS-6R centrifuge) for 5 min at 4°C followed by filtration through a 0.22-μm filter (Pall Co.) into sterile polypropylene tubes and kept on ice until used. ADC stock solutions were added to plasma at a final concentration of 100 μg·ml −1 . ADC vehicle with 0.5% BSA was used as a control matrix.
Aliquots of 100 μl from each mixture were transferred into sialated microcentrifuge tubes and incubated at 37°C in a CO 2 incubator with gentle rotation, to maintain the plasma pH levels close to the physiological pH of 7.2 throughout the incubation period. To stop the reaction, samples were first transferred to dry ice at predetermined time points (0.01, 8, 24, 48, and 96 hr) and then stored in a −80°C freezer.
The sample at 0.01 hr was collected within the first minute after adding the conjugate to the plasma.
| Efficacy studies in human tumour xenograft mouse models
All animal studies were conducted in compliance with National Institutes of Health (Bethesda, MD) guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at Genentech, Inc. Human tumour cells (20 × 10 6 cells in 0.2-ml HBSS; Hyclone) were inoculated subcutaneously into the flanks of female CB17 severe combined immunodeficient (SCID) mice (Charles River Laboratories [IMSR Cat# CRL:236, RRID:IMSR_CRL:236]). When mean tumour size reached about 150 mm 3 , the mice were divided into groups of 8 to 10 with the same mean tumour size and dosed i.v. via the tail vein with ADCs or unconjugated antibodies. Treatment information was not blinded during tumour measurement. Tumours were measured in two dimensions (length and width) using calipers, and tumour volume was calculated using the formula: Tumour size (mm 3 ) = 0.5 × (length × width × width).
The results were plotted as mean tumour volume ± SEM of each group over time. Partial response was defined as a tumour regression of >50% but <100% of the initial tumour volume, and complete response was defined as 100% tumour remission (i.e., no detectable tumour) on any given day during the study.
| PK study in SCID mice
The PK study in SCID mice was approved by the Institutional Animal Care and Use Committee at Genentech, Inc. Female SCID mice received a single i.v. dose of 5 mg·kg −1 of either polatuzumab vedotin or surrogate ADC and their corresponding unconjugated antibodies, via the tail vein (n = 20 per group). Due to the limited blood volume in mice, serial samples from the same mouse for all time points were not feasible. Instead, blood samples were collected via retro-orbital bleeds conducted on alternate eyes, and the terminal blood sample was collected via cardiac stick from each animal in each dosing group at the following time points: pre-dose; 5 min; 1, 6, and 24 hr; and 2, 3, 7, 10, 14, 21, and 28 days post-dose, and processed to collect plasma.
Three blood samples were taken from each mouse, and there were four mice per time point. Plasma concentration-time data were used to estimate relevant PK parameters. The reversibility, persistence, or delayed occurrence of any effects was assessed during the 6-week recovery period. Blood was collected pre-dose and at selected time points throughout the study for analyses of haematology, serum chemistry, coagulation, and TK.
| Multiple dose toxicity and TK study in Sprague-Dawley rats
Additionally, functional observational battery and motor activity assessments were conducted to determine impact on neurobehavioral systems. At scheduled terminal and recovery necropsies, tissues were grossly examined, collected, preserved, and processed for histological assessments.
| Multiple dose toxicity and TK study in cynomolgus monkeys
This study was performed under GLP compliance at Charles River Laboratories (Reno, NV). Experimentally naïve male and female cynomolgus monkeys (N = 5 per sex per group) were given an i.v. injection of vehicle, 1, 3, or 5 mg·kg −1 of polatuzumab vedotin or 3 or 5 mg·kg −1 of surrogate ADC once every 3 weeks (Q3W) for a total of four dose cycles (on Study Days 1, 22, 43, and 64). The Q3W i.v. dosing regimen was used to support the intended treatment regimen in patients. A terminal necropsy was conducted 1 week after the last dose (Day 71) to assess adverse effects associated with repeated polatuzumab vedotin and surrogate ADC administration and after a 9-week recovery period to assess reversibility of toxicity and the pharmacodynamic response of decrease in B cells mediated through CD79b. The length of this recovery period was selected based on confirmation of repletion of circulating B cells to ≥40% of baseline values by 9 weeks post-dose. Blood was collected pre-study and at selected time points throughout the study for analyses of haematology, serum chemistry, coagulation, TK, anti-drug antibodies, and measurement of circulating lymphocyte populations by flow cytometry. In addition, ophthalmic and physical examinations were conducted during the pre-dose phase and at the end of the first and last dose cycles. Safety pharmacology assessment was also conducted as a part of this study and included cardiovascular (ECG and haemodynamic endpoints in surgically implanted telemetry animals), respiratory, and neurobehavioral endpoints. At scheduled terminal and recovery necropsies, tissues were grossly examined, collected, preserved, and processed for histological assessments.
| Immunophenotyping of circulating lymphocyte populations by flow cytometry
Immunophenotyping analyses were conducted as part of the multiple dose toxicity study in monkeys. Flow cytometric assays were used to determine the percentage of lymphocyte-gated CD3 + T cells, CD3 + CD4 + T helper cells, CD3 + CD8 + cytotoxic T cells, CD3 − CD20 − NK cells, and CD20 + B cells in peripheral blood at Pre-dose Study Days −14, −7, and 1 and at Post-dose Study Days 2, 8, 22, 29, 43, 50, 64, 71, 85, 99, 113, 120, and 127 . Samples were analysed according to Charles River Laboratory SOP. In brief, peripheral blood samples were collected from each animal and aliquoted into 96-well plates containing saturating concentration of one or more of the fluorescently conjugated anti-CD3, -CD4, -CD8, and -CD20 antibody or the respective isotype controls. Samples were mixed and allowed to be incubated at room temperature in the dark for 30 min followed by 10 min of incubation in red blood cell lysis solution. Samples were then centrifuged and washed once with CRL (Charles River Laboratories) flow cytometry staining buffer followed by immediate acquisition on the BD FACSCanto™ II Flow Cytometer (BD Biosciences [RRID: SCR_013311]). Data were analysed using BD FACS DIVA ® 6. 
| Bioanalysis of serum and plasma samples from PK and toxicity studies
Total antibody and antibody-conjugated MMAE (acMMAE) were measured to characterize the non-clinical PK for polatuzumab vedotin and the surrogate ADC (Gorovits et al., 2013) .
Mouse plasma concentrations of total antibody (including fully conjugated, partially deconjugated, and fully deconjugated either anti-human CD79b antibodies or anti-cynomolgus monkey CD79b antibodies) and unconjugated antibody following a single administration of polatuzumab vedotin or surrogate ADC, and their corresponding unconjugated antibodies, respectively, were analysed by a bridging ELISA method (Kozak et al., 2013) . The ELISA The serum total antibody concentrations were calculated by fitting the data with a four-parameter model using Watson LIMS version 7.2.0.04 (Thermo Fisher, Waltham, MA). The minimum reportable value was 150 and 60 ng·ml −1 for polatuzumab vedotin total antibody and surrogate ADC total antibody, respectively. A similar nonvalidated assay was used to quantify total antibody concentrations in the in vitro plasma stability study; the minimum reportable value was 100 and 75 ng·ml −1 for polatuzumab vedotin total antibody and surrogate ADC total antibody, respectively.
| PK data analysis and statistics
Mouse plasma concentration-time data for a naïve pool of animals from all groups were used to estimate PK parameters using WinNonlin 
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) . 3.2 | Binding affinity of polatuzumab vedotin, the surrogate ADC, and their respective antibodies to human and cynomolgus monkey CD79b-expressing BJAB cells
The binding affinities of polatuzumab vedotin, clinical antibody, surrogate ADC, and the surrogate antibody to human and cynomolgus monkey CD79b were determined by radio-labelled, equilibrium binding assays using CD79b-transfected BJAB cells. Polatuzumab vedotin demonstrated high binding affinity to human CD79b (Table 1 ). The binding affinity of polatuzumab vedotin appeared similar to that of the unconjugated clinical antibody confirming that the antibody maintains antigen binding integrity and affinity after conjugation. Similarly, the surrogate ADC and the unconjugated surrogate antibody bound to cynomolgus monkey CD79b with high affinities (Table 1) . Furthermore, the binding affinity of surrogate ADC to cynomolgus monkey CD79b was similar to that of polatuzumab vedotin to human CD79b.
FIGURE 2
Species-specific binding of polatuzumab vedotin and the surrogate antibody-drug conjugate (ADC) to B cells. Polatuzumab vedotin, surrogate ADC, or isotype control (Hu anti-HER2 4D5), labelled with Zenon Alexa Fluor 647, were incubated with human, cynomolgus monkey, rat, and mouse PBMCs, isolated from whole blood. To allow for gating on CD20-positive B cells (human and cynomolgus monkey, isotype control), CD45RA-positive B cells (rat), or CD45R-positive B cells (mouse), the cells were co-stained with PE murine anti-human CD20 antibody, PE murine anti-rat CD45RA antibody, or PE rat anti-mouse CD45R antibody, respectively. After washing, cells were fixed with paraformaldehyde/PBS, and flow cytometry was performed on a BD FACSCalibur (BD FACSCalibur Flow Cytometry System, RRID:SCR_000401). The geometric mean fluorescence intensity, indicative of the extent of binding, was recorded for each sample, and the data were analysed using FlowJo v8.4.5 software
| Binding activity of polatuzumab vedotin, the surrogate ADC, and their respective antibodies to human FcγRs
Binding to human FcγRs was assessed by ELISA. Polatuzumab vedotin, unconjugated clinical antibody, surrogate ADC, and the unconjugated surrogate antibody showed comparable binding to human Fcγ receptors: FcγRIA, two allotypes of FcγRIIA (H131 and R131), FcγRIIB, and two allotypes of FcγgRIIIA (F158 and V158; Table S1 ). Similar binding between the ADCs and their corresponding unconjugated antibodies demonstrated that binding to FcγRs was not compromised by the conjugation process. Polatuzumab vedotin demonstrated similar binding to FcγRIA as compared with the surrogate ADC and twofold to threefold reduced binding activity to the rest of the receptors tested (Table S1 ).
| In vitro linker-drug stability of polatuzumab vedotin and surrogate ADC in human and animal plasma
To evaluate the stability of the linker in the ADC molecule and to evaluate any species differences, in vitro plasma stability studies were conducted. A comparable decrease across species was observed in the total antibody concentration following incubation of polatuzumab vedotin or surrogate ADC in plasma over time. Most of the decrease in concentration occurred during the first 24 hr of the study, with a more gradual decrease for the remainder of the 96 hr ( Figure S1a,b) .
The acMMAE concentrations, which are a measure of the amount of MMAE conjugated to polatuzumab vedotin or surrogate ADC, decreased gradually over the 96-hr study in all species tested ( Figure S1c,d) . The proportion of acMMAE, relative to time 0.01 hr, decreased to approximately 60% at 96 hr for all species. Overall, the in vitro plasma stability with polatuzumab vedotin and surrogate ADC were comparable across species and between the two ADCs.
| Efficacy of polatuzumab vedotin and the surrogate ADC against human Burkitt's lymphoma xenograft in SCID mice
To compare the anti-tumour activity of the surrogate ADC and polatuzumab vedotin, a tumour xenograft model of human Burkitt's lymphoma (BJAB-PD.cyCD79b.E3) expressing similar amounts of surface cynomolgus monkey and human CD79b was employed (Zheng et al., 2009) . Polatuzumab vedotin and the surrogate ADC showed comparable inhibition of tumour growth (Figure 3) . The unconjugated clinical antibody, unconjugated surrogate antibody, and the nonbinding control ADC administered at 2 mg·kg −1 had minimal effects on tumour growth, demonstrating that FcγR-mediated effector functions (e.g., antibody-dependent cell-mediated cytotoxicity) are not the primary mechanism of action of both ADCs. Therefore, comparable tumour growth inhibition by both ADCs was thought to be driven by CD79b-expressing tumour cells (Polson et al., 2007) , indicating that unconjugated antibody-mediated immune effector functions do not play an essential role in the anti-tumour efficacy.
3.7 | PK of polatuzumab vedotin, the surrogate ADC, and their respective unconjugated antibodies in SCID mice
Polatuzumab vedotin and the surrogate ADC do not bind to mouse CD79b. Therefore, the antigen-independent PK of polatuzumab vedotin, the surrogate ADC, and their corresponding unconjugated antibodies were characterized and compared in SCID mice. The PK profiles of both unconjugated antibodies following a single 5 mg·kg −1 i.v. dose and total antibody following a single i.v. dose of either polatuzumab vedotin or the surrogate ADC at 5 mg·kg −1 are shown in Figure 4 ; PK parameters are summarized in Table S2 .
Overall, PK profiles of the two unconjugated antibodies were comparable and characterized by a short distribution phase and a long elimination phase (Figure 4a ). The PK of total antibody following administration of the ADCs was also similar between the two ADCs and characterized by a slow CL and a long elimination half-life of 10-12 days. The PK profile was similar to that typically seen with most mAbs (Deng et al., 2011) . Additionally, acMMAE plasma concentrations following administration of polatuzumab vedotin or the surrogate ADC were comparable between the two ADCs ( Figure 4b ). acMMAE plasma concentrations decreased over time in a manner similar to the total antibody concentrations for both ADCs, indicating that MMAE is not rapidly released from polatuzumab vedotin or the surrogate ADC in mice and, as expected, the PK of the ADC is driven by the antibody component of the ADC.
| Toxicity and TK of polatuzumab vedotin in rats
The antigen-independent toxicity profile of polatuzumab vedotin was assessed in rat, a non-binding species. Polatuzumab vedotin administration was generally well tolerated up to 6 and 10 mg·kg −1 in males and females, respectively, when it was given at 2, 6, or 10 mg·kg −1 weekly for four doses. One of 15 males given 10 mg·kg −1 of polatuzumab vedotin was killed in moribund condition, with significant bone marrow toxicity. The main toxicology findings at 6 and 10 mg·kg −1 dose levels were bone marrow toxicity, thymic lymphoid depletion, and hepatobiliary toxicity ( Table 2) . Reproductive toxicity was limited to male testes and epididymitis. Additionally, in the lung, alveolar macrophage infiltrates accompanying hyperplasia/ hypertrophy of type II pneumocytes were identified. Nevertheless, the histological findings were completely reversible after a 6-week recovery period, with the exception of residual effects in the liver of one 10 mg·kg −1 female, in the lungs of one 10 mg·kg −1 male, and the testicular and epididymal toxicity observed at all doses in male rats.
These histological findings were consistent with the pharmacological effects of MMAE resulting in mitotic arrest, particularly in tissues with a high background mitotic rate.
As predicted for a non-binding species, the exposure of total antibody following i.v. administration of polatuzumab vedotin was dose proportional with moderate accumulation observed after repeated weekly doses (Table S3 ). The severely toxic dose in 10% of animals (STD 10 ) was determined to be 10 mg·kg −1 based on adverse effects on haematopoiesis and the bone marrow.
3.9 | Pharmacodynamics, TK, and toxicity of surrogate ADC and polatuzumab vedotin in cynomolgus monkeys
To confirm the antigen-independent toxicity profiles of polatuzumab vedotin observed in rats and to determine the PK/pharmacodynamics (PD) and safety from targeting CD79b, both polatuzumab vedotin and the surrogate ADC were assessed in cynomolgus monkeys.
Polatuzumab vedotin was administered i.v. every 3 weeks for four doses at 1, 3, or 5 mg·kg −1 , and the surrogate ADC was also adminis- (Mager, 2006) . No accumulation was observed with polatuzumab vedotin. The accumulation ratio 
Note. All toxicity findings were dose dependent in nature and reversible by the end of the recovery period, with the exception of findings in the testicles.
Abbreviations: ADC, antibody-drug conjugate; F, female; HNSTD, highest non-severely toxic dose; M, male; Ns, number of animals; Q1W, once weekly; Q3W, once every 3 weeks; STD, severely toxic dose.
(AUC 63-84 /AUC 0-21 ) for the surrogate ADC ranged from 1.22 to 1.52 (Table S4) . Although immunogenicity was observed in both ADCtreated groups, it did not appear to affect the TK exposures ( Figure 5b and Table S4 ).
Doses of up to 5 mg·kg −1 of polatuzumab vedotin and 3 mg·kg −1 of surrogate ADC were well tolerated in cynomolgus monkeys with no adverse effects on body weight or clinical evidence of toxicity, including an absence of cardiovascular, respiratory, or neurological effects, as part of safety pharmacology assessments (Table 2) (Bussiere et al., 2009; Clarke et al., 2004; Green & Terrell, 1992; Treacy, 2000) .
In the case of polatuzumab vedotin, a three-amino acid difference in the CD79b between human and cynomolgus monkey conferred selec- showed faster CL of the ADC and complete histological absence of splenic lymphoid follicular germinal centres at Day 71 (7 days after the last dose) and with the return of follicular germinal centres in spleen, after a 9-week recovery period. These data were previously reported by Fuh et al. (2017) and suggest that in vivo depletion of As part of the investigational new drug application to enable firstin-human dosing trials, the surrogate ADC was tested in cynomolgus monkeys to evaluate both antigen-dependent and -independent effects on toxicity, PK, and PD. Additionally, antigen-independent as well as MMAE-mediated effects of polatuzumab vedotin were assessed in both cynomolgus monkeys and rats. This approach has been employed by other pharmaceutical companies developing ADC therapeutic agents and has been accepted by the Food and Drug Administration. The predominant findings associated with administration of polatuzumab vedotin and the surrogate ADC included reversible bone marrow toxicity and associated haematological effects in both rats and monkeys, which were considered MMAE related and antigen independent. In rats, we evaluated polatuzumab vedotin but not the surrogate ADC. Previously, we tested a slightly different structural variant of polatuzumab vedotin and the corresponding monkey surrogate ADC in rats. We found that the toxicities were driven only by MMAE, as expected, and not the linker or antibody component of the ADC. To enable entry of polatuzumab vedotin into clinical trials, we concluded that testing of the surrogate ADC in rat was not beneficial to inform the first-in-human study. We also wanted to minimize the use of animals in the spirit of 3Rs-replace, reduce, and refine (Prescott & Lidster, 2017) . In cynomolgus monkeys, as expected, target (B cell)-mediated CL was observed with the surrogate ADC but not with polatuzumab vedotin (Mager, 2006) . Thus, at the same dose level, the systemic exposure of total antibody following i.v. administration of polatuzumab vedotin was 1.2-to 1.4-fold higher than that of the surrogate ADC in monkeys. However, this difference in exposure was not associated with any differences in toxicity between polatuzumab vedotin and the surrogate ADC in monkeys, confirming that the bone marrow toxicity observed with both ADCs was driven mainly by the antigen-independent effects of MMAE (Saber & Leighton, 2015) .
The highest non-severely toxic dose was determined to be 
